The international multicenter CE Mark clinical trial of the HeartMate 3 Left Ventricular Assist System included 50 patients. Thirty-day survival was 98%, bleeding and strokes were observed in 30% and 4%, respectively.
You are here:
Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes
Submitted by: CTSNet Staff
Source: Eur J Cardiothorac Surg
Keywords:
Author(s): Daniel Zimpfer, Ivan Netuka, Jan D. Schmitto, Yuriy Pya, Jens Garbade, Michiel Morshuis, Friedhelm Beyersdorf, Silvana Marasco, Vivek Rao, Laura Damme, Poornima Sood, and Thomas Krabatsch
Related Content
JANS Article
By: EACTS Staff
